Greenwich LifeSciences 3Q 2026: EPS ($0.4) — 10-Q Summary
Greenwich LifeSciences reported no revenue, with a net loss of $5.81M and EPS of -$0.40 in Q3 2026. R&D costs rose 67% due to clinical expenses, while G&A costs fell 12%. The company is expanding its Phase III trial for GLSI-100 globally. Cash reserves were $5.9M, but additional capital is needed for long-term operations, according to the company.
How this was made

The 30-second read
Why it matters
For traders, the key decision inputs are the widened loss, the magnitude of R&D expense growth, and the explicit statement that additional capital is needed, which can affect valuation and financing expectations.
Market read
The 10-Q summary signals higher burn and runway risk while confirming continued Phase III expansion, creating a mixed but liquidity-negative setup.
What to watch
Cash at Sept. 30 is only a snapshot; investors will also weigh any subsequent financing, milestone payments, or changes in trial enrollment pace not captured in this brief.
Background
The piece summarizes Greenwich LifeSciences’ 10-Q, highlighting lack of revenue, rising clinical spend, and liquidity constraints alongside Phase III trial activity.
Ticker impact
Greenwich LifeSciences reported a widened net loss and no revenue, with R&D up 67% and cash of $5.9M at Sept. 30, 2026.
Likely downside bias as investors price higher burn and potential capital needs, despite ongoing Phase III progress.
The article provides concrete quarterly financial deterioration (net loss, R&D increase) and explicit liquidity warning (additional capital needed), which typically drives biotech risk repricing.
Market effects
Reinforces typical pre-revenue biotech investor focus on burn rate, clinical expense ramp, and runway versus trial expansion.
No clear regional macro linkage beyond US-listed biotech risk sentiment.
Phase III Europe expansion may modestly affect global breast-cancer trial sentiment, but the article is primarily company-specific.
Counterpoint
The R&D increase is tied to clinical expenses and trial expansion (Flamingo-01 into Europe), which could improve probability of success and de-risk timelines.
Key entities
- companyGreenwich LifeSciences, Inc.
Pre-revenue biotech reporting widened net loss, higher R&D costs, and cash of $5.9M at Sept. 30, 2026, while expanding Phase III Flamingo-01 into Europe.
- clinical_programGLSI-100 (Flamingo-01)
Phase III trial evaluating prevention of breast cancer recurrence, expanding into Europe with plans for up to 150 global sites.
